Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 14, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions. The only financial data points present are the transaction prices for the notional re-investment of dividends:
- Ordinary shares: GBP 12.38 per share
- Ordinary Share ADRs: $51.25 per ADR
Material Changes
The filing details an increase in notional interests in Ordinary shares and ADRs for various executives following the notional re-investment of the dividend paid to shareholders on January 10, 2008. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period. The transactions were notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the vesting schedule and conditions for the Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares and ADRs held by the listed executives (Dr. J-P Garnier, Mr. A P Witty, Mr. D M Stout, etc.) to assess insider ownership concentration.
- Review the dividend payment date of January 10, 2008, to correlate with the re-investment transaction date of February 14, 2008.